• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Neuronetics Inc.

    6/28/24 3:04:39 PM ET
    $STIM
    Medical/Dental Instruments
    Health Care
    Get the next $STIM alert in real time by email
    SC 13G 1 stim_13gv3.htm

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

     

    (Amendment No.)*

     

     

    Neuronetics, Inc.
    (Name of Issuer)
     
    Common Stock, $0.01 par value
    (Title of Class of Securities)
     
    64131A105
    (CUSIP Number)
     
    June 18, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    o Rule 13d-1(b)
    x Rule 13d-1(c)
    o Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 64131A10513GPage 1 of 9 Pages

     

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Partners LP

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,500,000

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,500,000

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.0% (See Note 1)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    PN

     

           

    (1)Based on 29,997,563 outstanding shares of Common Stock (as defined in Item 2(d) below) as of May 3, 2024 represented in the Issuer's 10-Q filed with the Securities and Exchange Commission ("SEC") on May 7, 2024.

     

     

    CUSIP No. 64131A10513GPage 2 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Kent Lake Capital LLC

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,500,000 (See Note 3)

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,500,000 (See Note 3)

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000 (See Note 3)

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.0% (See Note 2)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IA, HC

     

           

    (2)See Note (1) Above.

     

    (3)Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC expressly disclaims beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC is the beneficial owner of any of the securities reported herein.

    CUSIP No. 64131A10513GPage 3 of 9 Pages

     

     

     

    1.

     

    NAME OF REPORTING PERSONS

    Benjamin Natter

     

     

    2.

     

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (see instructions)

    (a)     o

    (b)     o

     

     

    3.

     

    SEC USE ONLY

     

     

    4.

     

     

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH

     

    5.

     

    SOLE VOTING POWER

    0

     

     

    6.

     

    SHARED VOTING POWER

    1,500,000

     

     

    7.

     

    SOLE DISPOSITIVE POWER

    0

     

     

    8.

     

     

    SHARED DISPOSITIVE POWER

    1,500,000

     

     

     

     

    9.

     

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,500,000

     

     

    10.

     

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    (SEE INSTRUCTIONS)

    o

     

     

    11.

     

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    5.0% (See Note 4)

     

     

    12.

     

     

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

    IN, HC

     

           

    (4) See Note (1) Above.

     

    CUSIP No. 64131A10513GPage 4 of 9 Pages

     

    Item 1(a).Name of Issuer:

     

    Neuronetics, Inc. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    3222 Phoenixville Pike

    Malvern, PA 19355

     

    Item 2(a).Name of Persons Filing:

     

    This statement is filed by the entities and persons listed below, who are collectively referred to herein as "Reporting Persons", with respect to the shares of Common Stock (as defined in Item 2(d) below) of the Company:

     

    (i)Kent Lake Partners LP

     

    (ii)Kent Lake Capital LLC

     

    (iii)Benjamin Natter

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    (i)Kent Lake Partners LP

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (ii)Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    (iii)Benjamin Natter

    c/o Kent Lake Capital LLC

    300 East 2nd Street, Suite 1510, #1033

    Reno, NV 89501

     

    Item 2(c).Citizenship:

     

    (i)Kent Lake Partners LP – DE

     

    (ii)Kent Lake Capital LLC – DE

     

    (iii)Benjamin Natter – USA

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, $0.01 par value per share (“Common Stock”)

     

    Item 2(e).CUSIP Number:

     

    64131A105

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not Applicable.

     

    CUSIP No. 64131A105 13G Page 5 of 9 Pages

     

     

     

    Item 4.Ownership

     

    (i)Kent Lake Partners LP

     

    (a)Amount beneficially owned: 1,500,000 (See Note 5)

     

    (b)Percent of class: 5.0% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,500,000 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

     

    (ii)Kent Lake Capital LLC

     

    (a)Amount beneficially owned: 1,500,000 (See Note 5)

     

    (b)Percent of class: 5.0% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,500,000 (see Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

     

    (iii)Benjamin Natter

     

    (a)Amount beneficially owned: 1,500,000 (See Note 5)

     

    (b)Percent of class: 5.0% (See Note 6)

     

    (c)Number of shares as to which the person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote: 1,500,000 (See Note 5)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of: 1,500,000 (See Note 5)

     

    CUSIP No. 64131A105 13G Page 6 of 9 Pages

     

     

    Note 5:

     

    Kent Lake Capital LLC is an investment advisor that is registered under the Investment Advisors Act of 1940. Kent Lake Capital LLC may be deemed to be the beneficial owner of all shares of Common Stock held by Kent Lake Partners LP ("the Fund"). Mr. Benjamin Natter, as Managing Member of Kent Lake Capital LLC, with the power to exercise investment and voting discretion, may be deemed to be the beneficial owner of all shares of Common Stock held by the Fund. Pursuant to Rule 13d-4 under the Securities Exchange Act of 1934, as amended, Kent Lake Capital LLC and Mr. Natter expressly disclaim beneficial ownership over any of the securities reported in this statement, and the filing of this statement shall not be construed as an admission that Kent Lake Capital LLC or Mr. Natter are the beneficial owner of any of the securities reported herein.

     

    Note 6:

     

    Based on 29,997,563 outstanding shares of Common Stock as of May 3, 2024 represented in the Issuer's 10-Q filed with the SEC on May 7, 2024.

     

    Item 5.Ownership of Five Percent or Less of a Class:

     

    Not Applicable.

      

    Item 6.Ownership of More Than Five Percent on Behalf of Another Person:

     

    Not Applicable.

      

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:

     

    See Note 5 above.

     

    Item 8.Identification and Classification of Members of the Group:

     

    Not Applicable.

      

    Item 9.Notice of Dissolution of Group:

     

    Not Applicable.

      

    CUSIP No. 64131A105 13G Page 7 of 9 Pages

     

     

    Item 10.Certifications:

     

    Each of the Reporting Persons makes the following certification:

     

    By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: June 28, 2024

     

     

     

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

    CUSIP No. 64131A105 13G Page 8 of 9 Pages

     

     

    EXHIBIT A

     

    Joint Filing Agreement Pursuant to Rule 13d-1

     

    This agreement is made pursuant to Rule 13d-l(k)(1) under the Securities Exchange Act of 1934, as amended (the "Act") by and among the parties listed below, each referenced to herein as a "Joint Filer". The Joint Filers agree that a statement of beneficial ownership as required by Sections 13(g) or 13(d) of the Act and the rules thereunder may be filed on each of his, her or its behalf on Schedule 13G or Schedule 13D, as appropriate, and that said joint filing may thereafter be amended by further joint filings. The Joint Filers state that they each satisfy the requirements for making a joint filing under Rule 13d-1(k).

     

     

    Dated:  June 28, 2024
         

    KENT LAKE PARTNERS LP

    By: Kent Lake GP LLC, its General Partner

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    KENT LAKE CAPITAL LLC

    By: /s/ Benjamin Natter

    Name: Benjamin Natter

    Title: Managing Member

     

     

    BENJAMIN NATTER

    By: /s/ Benjamin Natter

     

     

     

     

    CUSIP No. 64131A105 13G Page 9 of 9 Pages

    Get the next $STIM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $STIM

    DatePrice TargetRatingAnalyst
    8/13/2024Outperform → Mkt Perform
    William Blair
    10/14/2021$18.00 → $12.00Market Outperform
    JMP Securities
    10/13/2021Outperform → Mkt Perform
    William Blair
    10/13/2021Buy → Neutral
    BTIG
    More analyst ratings

    $STIM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Cascella Robert bought $75,000 worth of shares (100,000 units at $0.75), increasing direct ownership by 28% to 453,098 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/13/24 5:02:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $20,000 worth of shares (25,000 units at $0.80), increasing direct ownership by 9% to 289,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      9/6/24 5:05:03 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Muir Glenn P bought $21,250 worth of shares (25,000 units at $0.85), increasing direct ownership by 10% to 264,818 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      8/30/24 5:15:02 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      MALVERN, Pa., June 19, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to one new non-executive employee as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics' Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient's continued service with the Company through the applicable vesting date, a

      6/19/25 7:00:56 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Clinical Presence at the 2025 Clinical TMS Society Annual Meeting and Progress in Greenbrook's Personalized Care Trial Program

      MALVERN. Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, is proud to share two significant updates underscoring its ongoing commitment to clinical excellence and innovation in mental health care. This week, NeuroStar will attend the 13th Annual Clinical TMS Society (CTMSS) Meeting, taking place June 11–14 in San Diego, CA as a Silver Sponsor. NeuroStar will present two poster presentations derived from the TrakStar® data set, the largest real-world outcomes database in TMS. Data hi

      6/10/25 8:31:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

      6/2/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Leadership Updates

    Live Leadership Updates

    See more
    • Neuronetics Set to Join Russell 2000® and Russell 3000® Indexes

      MALVERN, Pa., June 02, 2025 (GLOBE NEWSWIRE) --  Neuronetics, Inc. (NASDAQ:STIM), a vertically integrated, commercial stage, medical technology and healthcare company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the leading neurohealth therapies in the world, today announced that it is set to join the broad-market Russell 3000® Index and the small-cap Russell 2000® Index at the conclusion of the Russell indexes annual reconstitution, effective after the US market opens on June 30, 2025. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strate

      6/2/25 4:30:00 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Dr. Mehdi H. Shishehbor Appointed Chief Medical Officer of Inquis Medical

      Renowned vascular disease expert joins Silicon Valley clinical stage medical device company developing next-generation thrombectomy technology Inquis Medical also announces appointment of Bruce Shook, serial medtech entrepreneur, to Board of Directors REDWOOD CITY, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Inquis Medical, Inc., a privately held medical device company focused on peripheral vascular innovations, today announced the appointment of distinguished interventional cardiologist and scholar, Mehdi H. Shishehbor, DO, MPH, Ph.D., as Chief Medical Officer. Dr. Shishehbor is the President of University Hospitals Harrington Heart and Vascular Institute where he is the Angela and Ja

      7/12/23 9:00:00 AM ET
      $STIM
      $ABMD
      Medical/Dental Instruments
      Health Care
    • Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors

      MALVERN, Pa., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help with the best neurohealth therapies in the world, today announced the appointment of Joseph H. Capper to its Board of Directors and as a member of the Audit Committee effective January 1, 2023. "Joe is well known and extremely well regarded in the med-tech community for his ability to advance company goals," said Rob Cascella, Chairman of the Board of Neuronetics. "His depth of experience with public companies and his passion for innovative medical technologies will

      12/29/22 4:29:00 PM ET
      $BEAT
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      8/13/24 10:26:16 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • JMP Securities reiterated coverage on Neuronetics with a new price target

      JMP Securities reiterated coverage of Neuronetics with a rating of Market Outperform and set a new price target of $12.00 from $18.00 previously

      10/14/21 8:41:45 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics downgraded by William Blair

      William Blair downgraded Neuronetics from Outperform to Mkt Perform

      10/13/21 12:25:53 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    SEC Filings

    See more
    • SEC Form SD filed by Neuronetics Inc.

      SD - Neuronetics, Inc. (0001227636) (Filer)

      6/2/25 4:31:33 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 8-K filed by Neuronetics Inc.

      8-K - Neuronetics, Inc. (0001227636) (Filer)

      5/28/25 7:11:18 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Neuronetics Inc.

      10-Q - Neuronetics, Inc. (0001227636) (Filer)

      5/6/25 7:30:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Rosengarten Megan was granted 30,000 shares, increasing direct ownership by 27% to 140,890 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:18 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Conley Sheryl L was granted 30,000 shares, increasing direct ownership by 16% to 214,390 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:13 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Director Amin Avinash was granted 30,000 shares, increasing direct ownership by 240% to 42,500 units (SEC Form 4)

      4 - Neuronetics, Inc. (0001227636) (Issuer)

      5/27/25 5:00:15 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Financials

    Live finance-specific insights

    See more
    • Neuronetics to Report First Quarter 2025 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release first quarter 2025 financial and operating results prior to market open on Tuesday, May 6, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/knieqjnc. To listen to the conference call on your telephone, participants may register for the

      4/22/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Neuronetics to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call

      MALVERN, Pa., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced that it plans to release fourth quarter 2024 financial and operating results prior to market open on Tuesday, March 4, 2025. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day. The conference call will be broadcast live in listen-only mode via webcast at https://edge.media-server.com/mmc/p/a3eb5opb. To listen to the conference call on your telephone, participants may register fo

      2/21/25 8:30:00 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • CORRECTION—Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results

      MALVERN, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- In a release issued earlier today under the same headline by Neuronetics, Inc. (NASDAQ:STIM), please note that in the second paragraph of the "Stockholders Approve Acquisition of Greenbrook TMS" section, it should say that the Company expects to achieve cash flow breakeven by the third quarter of 2025, not the second. The corrected release follows: Neuronetics, Inc. (NASDAQ:STIM) (the "Company" or "Neuronetics") a commercial stage medical technology company with a strategic vision of transforming the lives of patients whenever and wherever they need help, with the best neurohealth therapies in the world, today announced its financial and ope

      11/12/24 6:45:48 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care

    $STIM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Neuronetics Inc.

      SC 13D - Neuronetics, Inc. (0001227636) (Subject)

      12/17/24 9:15:11 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 1:42:23 PM ET
      $STIM
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Neuronetics Inc.

      SC 13G/A - Neuronetics, Inc. (0001227636) (Subject)

      11/14/24 11:17:47 AM ET
      $STIM
      Medical/Dental Instruments
      Health Care